George D. Demetri, MD, director, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, discusses the trial the led to the approval of trabectedin (Yondelis) for advanced leiomyosarcoma or liposarcoma.
George D. Demetri, MD, director, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, discusses the trial the led to the approval of trabectedin (Yondelis) for advanced leiomyosarcoma or liposarcoma.
In this preplanned analysis, researchers were trying to limit any excess heterogeneity in order to get a clear answer as to whether trabectedin is more active than dacarbazine. There is no question, Demetri says, that there was a progression-free survival (PFS) difference but no overall survival (OS) difference.
Demetri says the lack of OS difference was due to post-study therapies virtually all patients went on to receive other agents after this protocol. It's worth noting, he says, that the trial was designed in 2010 and pazopanib (Votrient) was approved in 2012.
Combining Avutometinib With Defactinib Yields High Response Rates in LGSOC
March 22nd 2024In heavily pretreated patients with recurrent low-grade serous ovarian cancer, the combination of avutometinib plus defactinib showing promising results within the phase 2 ENGOT-ov60/GOG-3052/RAMP 201 trial.
Read More
Ixabepilone/Bevacizumab Improves PFS and OS in Platinum-Resistant/Refractory Ovarian Cancer
March 19th 2024Combining ixabepilone with bevacizumab generated improved survival rates and high response rates compared with ixabepilone monotherapy in platinum-resistant or platinum-refractory ovarian cancer.
Read More